ALK and non-small cell lung carcinoma: However, crizotinib (XALKORI®, Pfizer Inc.), an ALK tyrosine kinase activity inhibitor, has been approved by the FDA in the United States for treating patients with ALK + advanced NSCLC [23] as well as in other countries, including China.